An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy

Trial Profile

An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Expanded access
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 06 Jun 2017 Results (n=45) assessing the safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results assessing safety presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 09 Jun 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top